TY  - JOUR
AU  - Martinez-Cuadron, David
AU  - Boluda, Blanca
AU  - Martinez, Pilar
AU  - Bergua, Juan
AU  - Rodriguez-Veiga, Rebeca
AU  - Esteve, Jordi
AU  - Vives, Susana
AU  - Serrano, Josefina
AU  - Vidriales, Belen
AU  - Salamero, Olga
AU  - Cordon, Lourdes
AU  - Sempere, Amparo
AU  - Jimenez-Ubieto, Ana
AU  - Prieto-Delgado, Julio
AU  - Diaz-Beya, Marina
AU  - Garrido, Ana
AU  - Benavente, Celina
AU  - Perez-Simon, Jose Antonio
AU  - Moscardo, Federico
AU  - Sanz, Miguel A
AU  - Montesinos, Pau
PY  - 2018
DO  - 10.1007/s00277-018-3229-5
UR  - http://hdl.handle.net/10668/12172
T2  - Annals of hematology
AB  - Clinical outcomes of patients with acute myeloid leukemia (AML) showing the first primary refractory or early-relapsed disease remain very poor. The Programa Español de Tratamientos en Hematología (PETHEMA) group designed a phase I–II trial using...
LA  - en
PB  - Springer
KW  - Idarubicin
KW  - Disease-Free Survival
KW  - Granulocyte Colony-Stimulating Factor
KW  - Hematopoietic Stem Cell Mobilization
KW  - Heterocyclic Compounds
KW  - Leukemia, Myeloid, Acute
KW  - Hematopoietic Stem Cell
KW  - Recurrence
TI  - A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
TY  - research article
VL  - 97
ER  -